Get started
Author

Wilson Guzman

The immunocytokine NHS-IL12 as a potential cancer therapeutic
2014 · Jonathan Fallon, Robert Tighe, et al. · Oncotarget · 167
PDF
Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models
2017 · Chunxiao Xu, Yanping Zhang, et al. · Clinical Cancer Research · 79
Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity
2020 · Ugur Eskiocak, Wilson Guzman, et al. · JCI Insight · 49
PDF
CTX-8573, an Innate-Cell Engager Targeting BCMA, is a Highly Potent Multispecific Antibody for the Treatment of Multiple Myeloma
2019 · Jennifer Watkins-Yoon, Wilson Guzman, et al. · Blood · 39
XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer
2023 · Kurt A Jenkins, Miso Park, et al. · Journal for ImmunoTherapy of Cancer · 27
PDF
XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
2023 · Ekta Patel, Natalia V. Malkova, et al. · Molecular Cancer Therapeutics · 19
PDF
Tumor-selective activity of XTX202, a protein-engineered IL-2, in mice without peripheral toxicities in nonhuman primates.
2021 · Jennifer O'Neil, Wilson Guzman, et al. · Journal of Clinical Oncology · 17
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two
2016 · Casey Ager, Matthew Reilley, et al. · Journal for ImmunoTherapy of Cancer · 17
PDF
719 XTX301, a protein-engineered IL-12, exhibits tumor-selective activity in mice without peripheral toxicities and is well tolerated in non-human primates
2021 · Ekta Patel, Natalia Malkova, et al. · Journal for ImmunoTherapy of Cancer · 4
PDF
568 XTX201, a protein-engineered IL-2, exhibits tumor-selective activity in mice without peripheral toxicities in non-human primates
2020 · Minjie Zhang, Wilson Guzman, et al. · Journal for ImmunoTherapy of Cancer · 4
PDF
587 Tumor-activated Fc-engineered anti-CTLA-4 monoclonal antibody, XTX101, demonstrates tumor-selective PD and efficacy in preclinical models
2020 · Kurt Jenkins, Parker Johnson, et al. · Journal for ImmunoTherapy of Cancer · 2
Abstract 3239: CTX-5861 mediated SIRPα blockade combines with tumor targeting antibodies, checkpoint blockade and/or CD137 agonism to elicit curative anti-tumor activity in syngeneic mouse models
2019 · Ugur Eskiocak, Wilson Guzman, et al. · Cancer Research · 2
972 Masked T cell engagers designed to drive potent synthetic anti-tumor immunity with favorable tolerability
2025 · Wilson Guzman, Justin Greene, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
Abstract 719: A tumor-activated PD1/IL2 bispecific molecule, designed to overcome IL-2 receptor-mediated clearance, improve tolerability and stimulate antigen-experienced CD8+ T cells in the tumor microenvironment of murine models
2024 · Ertan Eryilmaz, Wilson Guzman, et al. · Cancer Research · 1
Abstract 572: Tumor-activated PD1-directed IL-2 increased antigen specific T cells in tumors and demonstrated anti-tumor activity in mice
2023 · Ertan Eryilmaz, Wilson Guzman, et al. · Cancer Research · 1
841 XTX202, a tumor-selective protein-engineered IL-2, exhibited enhanced anti-tumor activity in combination with checkpoint inhibition in mice
2022 · Wilson Guzman, Uli Carl Bialucha, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
Supplementary Table S2 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
2026 · Ekta Patel, Natalia V. Malkova, et al.
Supplementary Figure S7 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
2026 · Ekta Patel, Natalia V. Malkova, et al.
Supplementary Figure S3 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
2026 · Ekta Patel, Natalia V. Malkova, et al.
Supplementary Figure S6 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
2026 · Ekta Patel, Natalia V. Malkova, et al.
Supplementary Table S3 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
2026 · Ekta Patel, Natalia V. Malkova, et al.
Supplementary Figure S5 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
2026 · Ekta Patel, Natalia V. Malkova, et al.
Supplementary Table S1 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
2026 · Ekta Patel, Natalia V. Malkova, et al.
Supplementary Figure S2 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
2026 · Ekta Patel, Natalia V. Malkova, et al.
Supplementary Figure S1 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
2026 · Ekta Patel, Natalia V. Malkova, et al.
Works count: 75
Citation count: 430
H-index: 8
I10-index: 8
Year
Topic
Type